LRH-1 (liver receptor homologue-1), a transcription factor and member of the nuclear receptor superfamily, regulates the expression of its target genes, which are involved in bile acid and cholesterol homoeostasis. However, the molecular mechanisms of transcriptional control by LRH-1 are not completely understood. Previously, we identified Ku80 and Ku70 as LRH-1-binding proteins and reported that they function as co-repressors. In the present study, we identified an additional LRH-1-binding protein, ILF3 (interleukin enhancer-binding factor 3). ILF3 formed a complex with LRH-1 and the other two nuclear receptor co-activators PRMT1 (protein arginine methyltransferase 1) and PGC-1α (peroxisome proliferator-activated receptor γ coactivator-1α). We demonstrated that ILF3, PRMT1 and PGC-1α were recruited to the promoter region of the LRH-1-regulated SHP (small heterodimer partner) gene, encoding one of the nuclear receptors. ILF3 enhanced SHP gene expression in co-operation with PRMT1 and PGC-1α through the C-terminal region of ILF3. In addition, we found that the small interfering RNA-mediated down-regulation of ILF3 expression led to a reduction in the occupancy of PGC-1α at the SHP promoter and SHP expression. Taken together, our results suggest that ILF3 functions as a novel LRH-1 co-activator by acting synergistically with PRMT1 and PGC-1α, thereby promoting LRH-1-dependent gene expression.
INTRODUCTION
LRH-1 (liver receptor homologue-1, also called NR5A2), an orphan member of the nuclear receptor superfamily, is expressed in endoderm-derived tissues such as liver, intestine and pancreas. In these tissues, LRH-1 plays an important role in bile acid and cholesterol homoeostasis, steroidogenesis, development and ovulation [1] . In the liver, LRH-1 binds to a cis-element called LRHRE (LRH-1 response element) and regulates the expression of target genes involved in the synthesis and transport of bile acids and cholesterol, including SHP (small heterodimer partner, also called NR0B2) [2, 3] , CYP7A1 (cytochrome P450, family 7, subfamily A, polypeptide 1) [4] and CYP8B1 [5] .
Four isoforms of LRH-1 have been identified, LRH-1 v1 (variant 1), LRH-1, FTF (fetoprotein transcription factor) and LRH-1 v2 [1, 6] . LRH-1 is identical with LRH-1 v1 except for a deletion of 46 amino acids corresponding to exon 2 [1, 4, 7] . LRH-1 v2 is another truncated version of LRH-1, with a deletion corresponding to exon 5 and no transactivation activity [1, 4] . FTF is the N-terminally truncated isoform of LRH-1 v1 [6] .
As for the other members of the nuclear receptor superfamily, LRH-1 is composed of A-F regions that contain the N-terminal A/B region, the highly conserved DNA-binding domain (C region), the C-terminal ligand-binding domain (E/F region) and the D region, which serves as a hinge between the C and the E/F regions. The A/B and the E/F regions are known as ligandindependent AF-1 (activation function-1) and ligand-dependent AF-2 respectively [8] .
The majority of nuclear receptors, which are regulated by steroid, retinoid and other non-polar ligands, regulate transcription in a ligand-dependent fashion. The binding of a ligand causes the repositioning of the ligand-binding domain, resulting in interaction with co-activators that modify histones, modulate chromatin structure or recruit the general transcriptional machinery [9] . LRH-1 is constitutively active [10] , but whether its activation is ligand-dependent is not known. The mechanisms of transcriptional activation mediated by LRH-1 have yet to be elucidated, but it seems likely that the transactivation activity of the constitutively activated LRH-1 is modulated by transcriptional co-regulators, such as PGC-1α (peroxisome proliferator-activated receptor γ co-activator-1α). These co-activators have been suggested to serve as 'protein ligands' of LRH-1 [11] . Several studies have also identified transcriptional co-regulators of LRH-1 [12] [13] [14] .
To identify LRH-1 cofactors, we previously performed a GST (glutathione transferase) pull-down assay using nuclear extracts from HeLa cells and GST fused to FTF, one of the LRH-1 isoforms. Two major protein bands specifically bound to LRH-1 were identified as Ku80 and Ku70 [15] . We also found other specific, but unidentified, bands; hence, we attempted to determine their identity using MS. In the present study, we identified three proteins, filamin, actinin-4 and ILF3 (interleukin enhancer-binding factor 3), as LRH-1-binding proteins. Of these, we focused on ILF3 as it has been reported to be involved in transcription.
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ILF3, also referred to as NF110 (nuclear factor 110), and its splicing variant NF90 are ubiquitously expressed at approximately the same level. Both ILF3 and NF90 have two dsRBMs (double-stranded RNA-binding motifs), but ILF3 has a longer C-terminal region [16] . It has been demonstrated that ILF3 and NF90 regulate several promoter activities, either positively or negatively depending on the promoter context [17] [18] [19] . Moreover, Tang et al. [20] reported that ILF3 interacts with PRMT1 (protein arginine methyltransferase 1), which acts as a co-activator of various nuclear receptors by methylating the histone H4 at Arg 3 . In addition, it was reported that the transcription factor YY1 (Yin and Yang 1) recruits PRMT1 to the YY1-activated promoter through NF90, resulting in H4-specific methylation [21] . In addition to histones, PRMT1 methylates PGC-1α [22] , which serves as a co-activator of a number of nuclear receptors including LRH-1 [11, 23] . The co-activator activity of PGC-1α is potentiated by PRMT1 methylation [22] .
On the basis of these reports, we investigated the role of ILF3 in LRH-1-regulated gene expression, particularly with regard to the functional relationship between ILF3, PRMT1 and PGC-1α.
EXPERIMENTAL

Antibodies
Antibodies against ILF3/NF90 (clone 21/DRBP76), PGC-1α and LRH-1 were purchased from BD Biosciences, Calbiochem and Perseus Proteomics respectively. Monoclonal antibodies for the c-Myc epitope tag (clone 9E10) and FLAG tag were obtained from Roche and Sigma-Aldrich respectively.
Plasmids
All plasmids expressing GST-fused proteins were as described previously [15] . The expression plasmid for c-Myc epitopetagged LRH-1 and the luciferase reporter plasmid containing the SHP promoter ( − 572 to + 10; GenBank ® accession number AF044315) were also described previously [15] . The expression plasmid for ILF3 (NF110b, GenBank ® accession number NM_017620) or FLAG-tagged ILF3 was generated by subcloning of PCR-amplified fragments from cDNA prepared from HeLa cells into the appropriate points of the multicloning site of the pCI vector (Promega) and pFLAG-CMV2 (Sigma-Aldrich) respectively. The full-length coding region for human PRMT1 (GenBank ® accession number NM_198318) was amplified by PCR and cloned into pFLAG-CMV2. To produce the C-terminaldeleted ILF3 (NF110b, amino acids 1-612), Arg 613 was replaced with a stop codon by site-directed mutagenesis. Fragments amplified by PCR and the mutated site in these expression plasmids were sequenced to verify DNA sequence fidelity. The reporter plasmid containing three LRHREs located upstream of the SV40 (simian virus 40) promoter and the luciferase gene (pGL3-LRHRE×3) was kindly provided by Dr Ryuichiro Sato (Department of Applied Biological Chemistry, The University of Tokyo, Tokyo, Japan) [14] . The expression plasmid for FLAGtagged mouse PGC-1α (pCMX-FLAG-mPGC-1α) was a gift from Dr Yasutomi Kamei (Department of Molecular Medicine and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan). To generate a mouse PGC-1α construct containing two tandemly arranged FLAG tags (2×FLAG-mPGC-1α), a fragment from pCMX-FLAG-mPGC-1α containing FLAG-mPGC-1α was inserted into pFLAG-CMV2 (Sigma-Aldrich).
siRNA (small interfering RNA) oligonucleotide
The following siRNA oligonucleotides for human ILF3 were designed by Pfeifer et al. [24] and synthesized by Nippon Genetics: siILF3-1 (sense, 5 -GGCAAACAAGGAGGCUACUdTdT-3 ; antisense, 5 -AGUAGCCUCCUUGUUUGCCdTdT-3 ) and siILF3-2 (sense, 5 -CUACAGUGGUAGUGGAGGCdTdT-3 ; antisense, 5 -GCCUCCACUACCACUGUAGdTdT-3 ). As a negative control, we used an siRNA against firefly luciferase: si-luciferase (sense, 5 -CGUACGCGGAAUACUUCGAdTdT-3 ; antisense, 5 -UCGAAGUAUUCCGCGUACGdTdT-3 ).
Cell culture
HeLa cells and HEK (human embryonic kidney)-293 cells were maintained in Eagle's MEM (minimal essential medium) supplemented with 10 % FBS (fetal bovine serum) (JRH Biosciences). HepG2 cells were maintained in MEM supplemented with 10 % FBS and 1 % non-essential amino acids (Gibco). H-4-II-E cells (DS Pharma Biomedical) were maintained in αMEM (Nacalai Tesque) supplemented with 10 % FBS.
Identification of ILF3 and GST pull-down assays
The identification of ILF3 was performed as described previously [15] . For MS, bands of interest were isolated and subjected to trypsin digestion, desalting and MALDI-TOF-MS (matrixassisted laser-desorption ionization-time-of-flight MS). Protein identification was facilitated by MASCOT. GST pull-down assays were performed as described previously [15] , but with antibodies against ILF3 and NF90. For GST pull-down assays followed by the immunoprecipitation of GSH eluate, GST-LRH-1 and LRH-1-associating proteins were eluted using 20 mM GSH under native conditions (pH 8.0). The eluate was then immunoprecipitated with one of the antibodies against ILF3, Ku80 and Ku70.
Immunoprecipitates were subjected to SDS/PAGE and detected with these antibodies.
Immunoprecipitation assays
The immunoprecipitation assay in Figure 1 (D) was performed as described by Novac et al. [25] with slight modifications. HEK-293 cells were plated in 100-mm-diameter dishes and transfected with c-Myc epitope-tagged LRH-1 and FLAG-tagged ILF3 expression plasmids using HilyMax (Dojindo) following the manufacturer's instructions. Intact HepG2 cells and H-4-II-E cells were also plated in 12 100-mm-diameter dishes and grown in culture medium. These cells were collected, suspended with ice-cold lysis buffer [50 mM Hepes, pH 7.9, 140 mM NaCl, 1 % Triton X-100, 1 mM EDTA, 1× protease inhibitor cocktail (Nacalai Tesque)], and disrupted through a 21-gauge syringe needle three times. Cell lysate was added to lysis buffer containing 12.5 % glycerol and centrifuged for 5 min at 750 g, and the nuclear pellet was resuspended in 500 μl of lysis buffer. The suspension was sonicated using a Handy Sonic UR-20P instrument (Tomy Seiko) (at level 10 for 10 s 25 times) and centrifuged for 10 min at 17 400 g. The soluble fraction was incubated with an antiIgG antibody against the c-Myc epitope tag, LRH-1 or normal mouse IgG as a control (Santa Cruz Biotechnology) overnight and subjected to precipitation with Protein A-Sepharose beads. The beads were washed five times with lysis buffer, and bound proteins were separated by SDS/PAGE and subjected to Western blotting. In the experiment shown in Figure 6 (B), HEK-293 cells transfected with Myc-LRH-1, FLAG-PRMT1 and 2×FLAG-PGC-1α were suspended in lysis buffer as described by Monsalve et al. [26] . The cell suspension was flash-frozen, thawed and centrifuged (10 min, 17 400 g). The supernatant was immunoprecipitated with antibodies against ILF3 or the c-Myc epitope tag. The immuno-complex was collected using Protein Immunoprecipitates were separated by SDS/PAGE followed by Western blotting using antibodies against the FLAG tag. A 2 % equivalent volume of lysate without immunoprecipitation was loaded as an input. (E) Immunoprecipitation assay under physiological conditions. Lysates from intact HepG2 cells and H-4-II-E cells were immunoprecipitated using an antibody against LRH-1. Immunoprecipitated proteins were detected with the anti-ILF3 antibody. (F) GST pull-down assay was performed as described in (B and C) using GST-LRH-1 (50 μg) and nuclear extracts from HeLa cells (2 mg). GST-LRH-1 and GST-LRH-1-bound proteins were eluted under native conditions (pH 8.0) with reduced GSH (20 mM). The eluate was immunoprecipitated with one of antibodies against LRH-1, Ku80 and Ku70. Normal IgG was used as a negative control. The immunoprecipitated proteins were analysed by Western blotting. A 1 % equivalent volume of the eluate without immunoprecipitation was loaded as an input.
A-Sepharose beads, washed with PBS and subjected to SDS/ PAGE. Bound proteins were detected by anti-FLAG antibodies.
ChIP (chromatin immunoprecipitation) and re-ChIP (sequential ChIP)
The ChIP and re-ChIP assays in Figure 2 were performed as described previously [27] with minor modifications. Intact HEK-293 cells (Figure 2A ) or HEK-293 cells overexpressing c-Myc-tagged LRH-1 and FLAG-tagged ILF3 ( Figure 2B ) were cross-linked and sonicated using a Handy Sonic UR-20P instrument (Tomy Seiko) at level 10 for 10 s 15 times. The immunoprecipitated chromatin complex was eluted as described previously [27] .
All ChIP assays in Figure 6 were conducted as described previously by Novac et al. [25] . HEK-293 cells were transfected with Myc-tagged LRH-1 and ILF3 along with FLAGtagged PRMT1 or 2×FLAG-tagged PGC-1α ( Figure 6A ). In Figure 6 (C), HEK-293 cells were treated with siRNA against ILF3 (1.5 nmol/10-cm-diameter dish) using Lipofectamine TM 2000 (Invitrogen), and then transfected with c-Myc-tagged LRH-1 and 2×FLAG-tagged PGC-1α using HilyMax (Dojindo). Cells were cross-linked, harvested, lysed and sonicated using a Handy Sonic UR-20P instrument (Tomy Seiko) at level 10 for 10 s 15 times. After passing through Protein A-Sepharose beads, lysates were incubated with antibodies against the c-Myc epitope tag, FLAG epitope tag, ILF3 or PGC-1α. Complexes were recovered by incubation with 0.4 μg/μl sheared salmon sperm DNA, 1 μg/μl BSA and Protein A-Sepharose beads. The beads were serially washed with wash buffer 1, wash buffer 2 [25] and twice with TE (Tris/EDTA) buffer. The precipitates were incubated with elution buffer as described previously [27] .
Eluates were reverse-cross-linked and digested with proteinase K (Roche). DNA was purified as described previously [27] . For PCR to amplify a 450-bp fragment of the SHP promoter (nucleotides − 508 to − 60), the following primers were used: forward, 5 -CTGCTTCTGGCTGACAACAGAAGC-3 ; and reverse, 5 -GAATGGCCCAACAACCTTGACTCC-3 .
The PCR products were separated by acrylamide gels and visualized by ethidium bromide staining. Each ChIP and re-ChIP assay was performed at least twice with similar results.
Luciferase reporter assays
The reporter assay was performed as described previously [15] . Briefly, HEK-293 cells were plated in 24-well plates and cultured for 16-20 h. The cells were transfected with 20 ng of the SHP promoter reporter plasmid, 50 ng of the reporter plasmid containing three LRHREs located upstream of the SV40 promoter ( Figure 2C , right-hand panel), 1 or 4 ng of the Myc-tagged LRH-1 expression plasmid (pCMV-Myc-LRH-1), varying amounts of the ILF3 expression plasmids (Figure 2, pCI-ILF3 ), 10 or 20 ng of the FLAG-tagged ILF3 expression plasmid (Figure 4 , pFLAG-CMV2-ILF3), 10 ng of the FLAG-tagged C-terminal-deletion ILF3 mutant expression plasmid (pFLAG-CMV2-ILF3 C), 10 or 20 ng of the FLAG-tagged PRMT1 expression plasmid (pFLAG-CMV2-PRMT1), and 5, 10 or 20 ng of the FLAG-tagged mouse PGC-1α expression plasmid (pCMX-FLAG-mPGC-1α) using HilyMax (Dojindo). In each case, total amounts of DNA were equalized by adding pCMV-Myc and pFLAG-CMV2. After 48 h of incubation, the cells were lysed and subjected to luciferase assays. Relative luciferase activity was calculated from the mean value relative to the activity of the reporter plasmid alone. Results shown represent means + − S.D. of triplicate transfections. Each transfection was done at least twice with similar results. All data were evaluated with Student's t tests.
Quantitative real-time PCR
HEK-293 cells were transfected with 2 ng of the Myc-tagged LRH-1 expression plasmid (pCMV-Myc-LRH-1), 20 or 40 ng of the FLAG-tagged ILF3 or PRMT1 expression plasmid (pFLAG-CMV2-ILF3 or pFLAG-CMV2-PRMT1), 20 ng of the FLAGtagged C-terminal-deletion ILF3 mutant expression plasmid (pFLAG-CMV2-ILF3 C), and 5 or 10 ng of the FLAG-tagged mouse PGC-1α expression plasmid (pCMX-FLAG-mPGC-1α) using HilyMax (Dojindo). Total DNA was kept constant by the addition of pCMV-Myc or pFLAG-CMV2. After 48 h of incubation, total RNA was isolated using TriPure Isolation Reagent (Roche).
For the experiment shown in Figure 3 (A), HepG2 cells were transfected with siRNA oligonucleotides (30 pmol/24-well plate) using Lipofectamine TM RNAiMAX (Invitrogen) and incubated for 12 h, followed by a change of medium. After 84 h of incubation, total RNA was extracted. In Figure 3 (B), siRNA-transfected HepG2 cells were treated with 50 μM CDCA (chenodeoxycholic acid) at 28 h post-transfection. After 24 h of incubation, total RNA was isolated.
cDNA was synthesized with 1 μg of total RNA and a random primer or oligo dT primer using ReverTra Ace-α-® (Toyobo). Quantitative real-time PCR was performed as described previously [27] . The predesigned primers and probe sets for SHP, CYP7A1, human GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and 18S rRNA were obtained from Applied Biosystems. The expression of SHP was normalized to that of GAPDH or the amount of 18S rRNA. The relative mRNA level was calculated from the mean value relative to the expression level shown in the first column (left-hand side) of each Figure  (Figures 3, 4B and 5C ). Results shown represent means + − S.D. of triplicate transfections. Each transfection was performed at least twice with similar results. All data were evaluated with Student's t tests.
Figure 3 Knockdown of ILF3 leads to a reduction in SHP expression
HepG2 cells in 24-well plates were transfected with 30 pmol of two different siRNA oligonucleotides against ILF3 (siILF3-1 and siILF-2). As a negative control, siRNA specific for firefly luciferase (siLuc) was used. (A) After 96 h, proteins and total RNA were extracted. (B) siRNA-transfected HepG2 cells were treated with 50 μM CDCA at 28 h post-transfection. After 24 h of incubation, proteins and total RNA were extracted. Proteins were subjected to SDS/PAGE followed by Western blotting using antibodies against ILF3 (left-hand panels in A and B). Total RNA was subjected to reverse transcription for preparing cDNA. The levels of SHP and CYP7A1 mRNA were determined by quantitative PCR and normalized to the 18S rRNA level. The relative mRNA level was calculated from the mean value relative to the control. Results are means + − S.D. of triplicate transfections. *P < 0.01.
RESULTS
Identification of ILF3 as a protein binding to LRH-1
In our previous study [15] , we performed a GST pull-down assay using nuclear extracts from HeLa cells and GST fused to the A-C region of FTF, one of the LRH-1 isoforms. Several proteins, ranging from 50 to 400 kDa, specifically bound to the A-C region of FTF were obtained. Among them, two major protein bands were identified as Ku80 and Ku70 [15] . To identify other proteins binding to FTF, the bands were excised, trypsin-digested and subjected to tandem MS. Their identity was determined by a MASCOT search. Polypeptides with a molecular mass of 280, 115 and 110 kDa were identified as filamin, actinin-4 and ILF3 respectively. Peptide sequences obtained from these polypeptides and their identities are shown in Table 1 . Among them, we focused on ILF3, which is involved in transcription as described above.
ILF3 interacts with LRH-1
To date, four isoforms of LRH-1, referred to as FTF, LRH-1 v1, LRH-1 and LRH-1 v2, have been reported ( Figure 1A ) [1, 6] . Therefore we examined whether ILF3 interacts with the A-C region of these isoforms, which differ in their length of the Nterminal region ( Figure 1B) . GST fused to the A-C regions of the three isoforms of LRH-1 was incubated with nuclear extracts from HeLa cells. To detect ILF3, we carried out a Western blot analysis using anti-ILF3 antibodies. In addition to FTF, ILF3 associated with the A-C regions of LRH-1 and LRH-1 v1.
The ILF3 gene produces two splicing variants, ILF3 (also referred to as NF110) and NF90 with apparent molecular masses of 110 kDa and 90 kDa respectively. ILF3 contains an extra 192 amino acids in the C-terminal region, which is rich in glycine, glutamine, serine and tyrosine residues ( Figure 1A ) [18, 19] . Although ILF3 and NF90 were expressed in approximately the same amounts in HeLa cells, as shown in the input lane of Figure 1 (B), ILF3, but not NF90, interacted with the A-C region of the three isoforms of LRH-1. Accordingly, ILF3 binds to the A-C region of LRH-1 in the C-terminal region. Considering that LRH-1 is the most abundant isoform in the human hepatoma cell line HepG2 and human adult and fetal liver [7] , we used LRH-1 for further studies.
To investigate whether ILF3 associates with full-length LRH-1 and which region of LRH-1 is responsible for the interaction with ILF3, a GST pull-down assay was performed using GSTfused proteins containing various regions of LRH-1. As shown in Figure 1 (C), ILF3 interacted with the full-length (A-F) form of LRH-1 in addition to the A-C region. To identify and characterize the region of LRH-1 that interacts with ILF3, LRH-1 was divided into the A-C and D-F regions, and each region was divided into the A/B and C and the D and E/F regions respectively. In the N-terminal A-C region, ILF3 interacted with the C region, the DNA-binding domain. Moreover, ILF3 associated with the D region, which is also referred to as the hinge region connecting the DNA and the ligand-binding domains. No interaction was observed between ILF3 and the A/B or E/F region of LRH-1. Taken together, these results suggest that the interaction between ILF3 and LRH-1 is mediated through the C-terminal region of ILF3 and the C and D regions of LRH-1.
To demonstrate the intercellular interaction between ILF3 and LRH-1 in vivo, we carried out an immunoprecipitation assay using HEK-293 cells co-transfected with FLAG-tagged ILF3 and c-Myc epitope-tagged LRH-1. Cells were lysed and immunoprecipitated with the anti-c-Myc antibody or the normal mouse IgG as a control. The immunoprecipitates were immunoblotted with the anti-FLAG antibody to detect FLAG-tagged ILF3. ILF3 was coprecipitated with LRH-1 using an antibody against the c-Myc epitope tag. The results shown in Figure 1 (D) indicate ILF3 interaction with LRH-1.
To determine whether ILF3 interacts with LRH-1 under physiologically relevant conditions, we next tested whether these proteins could be co-immunoprecipitated from untransfected cell lysates of human hepatoma HepG2 cells and rat hepatoma H-4-II-E cells. Following immunoprecipitation by the anti-LRH-1 antibody, the endogenous ILF3 was co-precipitated with LRH-1 and detected with the anti-ILF3 antibody in both cell lines, indicating that these two proteins form a complex under physiological conditions ( Figure 1E ).
Because we previously identified Ku80 and Ku70 as proteins bound to LRH-1 [15] , we next examined whether ILF3 and Ku proteins are simultaneously present in the complex with LRH-1. We conducted a GST pull-down assay followed by an immunoprecipitation of the eluate from GSH-Sepharose. First, proteins bound to LRH-1 were collected by incubation of GST-LRH-1 with nuclear extract from HeLa cells and eluted with GSH. As shown in the input lane of Figure 1 (F), ILF3, Ku80 and Ku70 were detected in the eluate. These proteins were then immunoprecipitated using one of the antibodies against ILF3, Ku80 and Ku70, and detected with each antibody by Western blotting. The three lanes on the right-hand side in Figure 1(F) show that the ILF3-LRH-1 complex contained neither Ku80 nor Ku70, and neither of the Ku protein-LRH-1 complexes co-existed with ILF3, suggesting that ILF3 and Ku proteins may form a discrete complex with LRH-1. In contrast, both Ku80 and Ku70 appeared to be present simultaneously in a complex with LRH-1.
ILF3 associates with LRH-1 on the SHP promoter
To investigate whether endogenous ILF3 is recruited to the SHP promoter, we performed a ChIP assay with an antibody against ILF3 using HEK-293 cells. The DNA obtained from immunoprecipitated chromatin was amplified using primers for the SHP promoter, which contains LRH-1-binding sites [2, 3] . As shown in Figure 2 (A), we found that ILF3 was associated with the SHP promoter region. To further determine whether ILF3 and LRH-1 were simultaneously associated with the promoter, c-Myc epitope-tagged LRH-1 and FLAG-tagged ILF3-expressing HEK-293 cells were subjected to re-ChIP. The chromatin fraction was first immunoprecipitated with antibodies against the c-Myc epitope tag and then re-immunoprecipitated with FLAG antibodies ( Figure 2B ). When LRH-1 was first immunoprecipitated, subsequent re-ChIP analysis revealed that ILF3 was co-immunoprecipitated with LRH-1. These results suggest that both ILF3 and LRH-1 are recruited to the same regions of the SHP promoter.
ILF3 enhances LRH-1 transactivation activity
The effects of ILF3 on the transactivation function of LRH-1 were tested using a luciferase reporter assay ( Figure 2C ). The SHP promoter reporter plasmid containing LRH-1-binding sites was transfected with expression plasmids for Myc-tagged LRH-1 and ILF3 into HEK-293 cells ( Figure 2C, left-hand panel) . ILF3 increased the promoter activity in a dose-dependent manner in the presence, but not absence, of exogenously expressed LRH-1.
We then used a reporter plasmid, containing three established LRHREs derived from three different genes located upstream of the SV40 promoter, and the luciferase gene [14] . HEK-293 cells were transfected with the LRHRE×3-SV40 reporter plasmid (pGL3-LRHREx3) and expression plasmids for Myctagged LRH-1 and ILF3 ( Figure 2C, right-hand panel) . ILF3 up-regulated the LRH-1-driven luciferase activity in a dosedependent manner. ILF3 did not affect the SV40 promoter (pGL3) in the presence of Myc-tagged LRH-1 (results not shown). These results demonstrate that ILF3 enhances the transactivation activity of LRH-1.
ILF3 knockdown in HepG2 cells results in decreased SHP gene expression
To evaluate the role of endogenous ILF3 in SHP expression, two different siRNAs targeting human ILF3, but not NF90 [24] , or luciferase as a control were transfected into human hepatoma HepG2 cells. Both siRNAs effectively reduced the ILF3 level, but not NF90 ( Figure 3A , left-hand panel), consistent with a previous report [24] . The ILF3 knockdown by siRNAs led to a decrease in SHP expression ( Figure 3A, right-hand panel) , strongly indicating that ILF3 plays an important role in the transcription of SHP, the LRH-1 target gene.
To further investigate the physiological relevance of ILF3 in bile acid metabolism, we next measured CYP7A1 gene expression using siILF3-1, which is highly effective in reducing the ILF3 expression level. CYP7A1, a rate-limiting enzyme in the classical bile acid-synthesis pathway, is regulated by LRH-1 and SHP, which represses CYP7A1 expression by heterodimerization with LRH-1 [3, 4, 28] . HepG2 cells transfected with siRNA were treated with bile acid (CDCA) and then CYP7A1 mRNA levels as well as SHP mRNA levels were determined. Western blot analysis confirmed that ILF3 was knocked down in both untreated and CDCA-treated cells ( Figure 3B, left-hand panel) . In the case of ILF3 knockdown, the expression of SHP and CYP7A1 decreased and increased respectively, irrespective of CDCA treatment ( Figure 3B , middle and right-hand panels). When treated with CDCA, SHP expression increased in ILF3-depleted cells, but not in control cells. With CDCA treatment, expression of CYP7A1 was impaired in the control cells, as reported previously [29] . Interestingly, this repressive effect was also observed in ILF3-depleted cells ( Figure 3B , middle and right-hand panels). Taken together, it is likely that ILF3 represses CYP7A1 gene expression mainly through the inhibition of SHP expression in a bile acidindependent fashion.
ILF3 enhances LRH-1-mediated promoter activity and SHP expression co-operatively with PRMT1 and PGC-1α
A previous report suggested that ILF3 interacts with PRMT1 to modulate PRMT1 activity [20] . PRMT1 also targets co-activator molecules, such as PGC-1α [22] , which has been shown to interact with LRH-1 [11] . We therefore hypothesized that ILF3 upregulates LRH-1-driven SHP promoter activity in co-ordination with PRMT1 and PGC-1α. To evaluate this, a reporter assay was performed with the SHP promoter reporter plasmid and expression plasmids for candidate cofactors ( Figure 4A ). Cotransfection of LRH-1 with ILF3, PRMT1 or PGC-1α resulted in increased promoter activity (columns [3] [4] [5] [6] [7] [8] . A combination of two of the three factors caused synergistic activation of the SHP promoter (columns 9-11). Moreover, co-transfection with all three cofactors resulted in a 135-fold increase over the control (column 12).
To further verify the combined effects of ILF3, PRMT1 and PGC-1α, we measured the mRNA level of SHP with realtime PCR. The LRH-1 expression plasmid was transfected into HEK-293 cells with expression plasmids for the three cofactors ( Figure 4B ). The SHP gene expression remained unaltered when ILF3 or PRMT-1 alone were co-transfected with LRH-1 (columns 2-6). However, PGC-1α expression led to an increase in the level of SHP mRNA (columns 7 and 8). ILF3 enhanced PGC-1α-mediated, but not PRMT1-mediated, SHP expression, although PRMT1 did not alter ILF3 or PGC-1α-dependent SHP expression (columns 9-11). Moreover, co-transfection of LRH-1 with ILF3, PRMT-1 and PGC-1α resulted in a 7-fold increase in the SHP expression (column 12). These results suggest that ILF3, PRMT1 and PGC-1α synergistically increase the promoter activity and the level of SHP mRNA.
ILF3 enhances the transactivation activity of LRH-1 through the C-terminal region
As demonstrated in a previous study, PRMT1 associates with the C-terminal region of ILF3 [20] . To investigate the contribution of the C-terminal region to the synergistic effect of ILF3, The reporter assay was performed as described in Figure 4 (A). Transfection conditions were as in Figure 4 (A) except for the following expression plasmids: FLAG-tagged mPGC-1α ( + , 5 ng) and FLAG-tagged ILF3 C ( + , 10 ng). To verify the expression level of FLAG-tagged ILF3 and FLAG-tagged ILF3 C, proteins were subjected to SDS/PAGE followed by Western blotting (WB) using an antibody against the FLAG tag. The protein level was representative of columns 3, 4, 7 and 8 (right-hand panel). (C) Quantitative real-time PCR was performed as described in Figure 4 (B), but with the FLAG-tagged ILF3 C ( + , 20 ng) expression plasmid.
PRMT1 and PGC-1α on SHP promoter activity, we generated a deletion construct lacking the C-terminal amino acids 613-898 (ILF3 C). Schematic diagrams of ILF3 and ILF3 C are shown in Figure 5 (A). The luciferase reporter plasmid containing the SHP promoter and the expression plasmids of LRH-1, ILF3, PRMT1 and PGC-1α were transiently transfected into HEK-293 cells ( Figure 5B ). Co-expression of ILF3 with PRMT1 and PGC-1α dramatically increased the reporter gene activity compared with an individual cofactor activity (columns 3-7). In contrast, co-expression of ILF3 C greatly reduced SHP promoter activity (column 8). In this experiment, the equivalent expression of ILF3 proteins was confirmed ( Figure 5B , right-hand panel).
To further examine the importance of the C-terminal region of ILF3, we evaluated endogenous SHP gene expression at the mRNA level when these cofactors were overexpressed in HEK-293 cells ( Figure 5C ). Overexpression of ILF3, PRMT1 or PGC-1α had no effect on SHP gene expression, whereas cotransfection of these factors resulted in a significant induction of the SHP gene (column 7). Furthermore, the combined effect of these three factors was abrogated by a deletion mutation (ILF3 C) with a loss of PRMT1-binding activity (column 8). Taken together, these results demonstrate that ILF3 acts as an LRH-1 co-activator with PRMT1 and PGC-1α through the Cterminal region of ILF3.
ILF3 is required for the recruitment of PGC-1α to the SHP promoter
Our reporter assay and observation of LRH-1 target gene expression demonstrated the synergistic action of ILF3, PRMT1 and PGC-1α (Figures 4 and 5) . Next, a ChIP assay was performed to determine whether PRMT1 and PGC-1α, in addition to ILF3, are recruited to the SHP promoter. For these experiments, HEK-293 cells expressing LRH-1 and ILF3 along with PRMT1 or PGC-1α were used. Cross-linked DNA fragments produced by sonication were immunoprecipitated with antibodies against the c-Myc epitope tag, ILF3, the FLAG-tag or PGC-1α. Immunoprecipitates were analysed by PCR using pairs of specific primers spanning the LRH-1-binding sites of the SHP promoter ( Figure 6A ). Consistent with the results of the ChIP assay in Figure 2 , LRH-1 and ILF3 were recruited to the SHP promoter region. Additionally, PRMT1 and PGC-1α were also associated with the SHP promoter ( Figure 6A , αFLAG and αPGC-1α lanes respectively).
To obtain further evidence that ILF3 co-operates with PRMT1 and PGC-1α, we examined whether PRMT1 and PGC-1α could be co-immunoprecipitated with LRH-1 or ILF3 from lysates prepared from HEK-293 cells transfected with Myc-LRH-1, FLAG-PRMT1 and 2×FLAG-PGC-1α using anti-ILF3 or antic-Myc epitope tag antibodies ( Figure 6B ). As previously reported [20] , PRMT1 interacted with ILF3 ( Figure 6B , lower panel, αILF3 lane). In contrast, no PGC-1α was detected in anti-ILF3 immunoprecipitates. When the lysate was precipitated with the anti-c-Myc epitope tag antibody, PGC-1α was coimmunoprecipitated with LRH-1, whereas PRMT1 was not. Taken together, ILF3 bound to PRMT1 more strongly compared with PGC-1α.
To examine the effect of ILF3 knockdown on the recruitment of PGC-1α to the SHP promoter, we performed a ChIP assay using ILF3-knockdown cells. To deplete ILF3, but not NF90, siRNA specifically directed at ILF3 was used. The siRNA-treated HEK-293 cells were subsequently transfected with Myc-LRH-1 and 2×FLAG-PGC-1α. Immunoblot analysis revealed that ILF3 was knocked down, and the protein levels of exogenously expressed LRH-1 and PGC-1α were indistinguishable ( Figure 6C , left-hand panel). Under these conditions, the association of PGC-1α with the SHP promoter was eliminated in cells transfected with siRNA specific for ILF3, compared with the control cells that were transfected with siRNA against luciferase. Collectively, our results suggested that ILF3, PRMT1 and PGC-1α were cooperatively recruited to the SHP promoter ( Figure 6C , right-hand panel).
DISCUSSION
In the present study, we identified ILF3 as a protein that interacts with LRH-1 and functions as its co-activator. In particular, we focused on the correlation between ILF3, PRMT1 and PGC-1α.
First, we demonstrated that ILF3 increased the promoter activity and SHP expression synergistically with PRMT1 and PGC-1α (Figure 4) . Secondly, the co-operative effects of these factors were abolished by overexpression of the C-terminal-deleted ILF3 ( Figure 5 ). Thirdly, we observed interactions between LRH-1 and ILF3, ILF3 and PRMT1, and LRH-1 and PGC-1α ( Figures 1D  and 6B ). Finally, our results indicated that ILF3 knockdown resulted in decreased binding of PGC-1α to the SHP promoter ( Figure 6C ). Collectively, these findings suggest that SHP gene expression is regulated by the concerted actions of ILF3, PRMT1 and PGC-1α. However, PRMT1 was not detected in the fraction immunoprecipitated by LRH-1 ( Figure 6B ). These observations raise the possibility that ILF3 stimulates the transactivation activity of LRH-1 by acting as a bridge between LRH-1, PRMT1 and PGC-1α through the C-terminal region of ILF3.
The C-terminal region unique to ILF3 is responsible for the association with LRH-1 (Figure 1) . Previous reports have also demonstrated that this C-terminal region is required for the interaction with proteins that are closely related to transcriptional regulation. It was reported that FUS (fused in sarcoma)/TLS (translocated in liposarcoma) and the survival of motor neuron were associated with ILF3, but not with NF90 [30] . Interestingly, FUS/TLS has also been identified as a protein that interacts with nuclear receptors [31] and is methylated by PRMT1 [32] . In addition, it has also been indicated that p68 and p72 RNA helicases, nuclear receptor co-activators, bind to the C-terminal region of ILF3 [33] . Given that the C-terminal GQSY-rich region is unique to ILF3, the co-activator function in LRH-1-mediated transactivation may also be unique to ILF3.
The deleted C-terminal region of ILF3 (amino acids 613-898) also contains a GAR (glycine/arginine-rich) region. Accumulating evidence has revealed that PRMT1 methylates arginine residues at RG, RGG and RGR repeats in the GAR region [34] . In addition to ILF3, NF90 also contains this RGG motif ( Figure 1A ) [18, 19] . A previous report demonstrated that ILF3 and NF90, but not ILF3 C, were methylated by PRMT1 [20] . This RGG motif may participate in the co-operative action between ILF3 and PRMT1.
The transcriptional regulation of genes involved in bile acid synthesis has been studied extensively. When the bile acid level increases, farnesoid X receptor is activated and induces SHP transcription. Elevated levels of SHP result in the repression of its own expression and that of CYP7A1 [3, 28] . In the present study, we showed the importance of ILF3 for the expression of SHP and CYP7A1 (Figure 3 ). Although these genes exhibited a reciprocal expression pattern, and it is possible that ILF3 suppresses CYP7A1 expression by enhancing SHP expression mediated by LRH-1 ( Figure 3B ), the CDCA-mediated repression of CYP7A1 observed in the control cells was independent of SHP mRNA levels, suggesting that other mechanisms underlie CYP7A1 expression. In fact, it has been reported that the bile aciddependent repression of CYP7A1 is also regulated by pregnane X receptor, c-Jun N-terminal kinase, HDAC-7 (histone deacetylase-7) or fibroblast growth factor-19 [35] [36] [37] [38] . Therefore we cannot rule out the possibility that ILF3 controls CYP7A1 expression by regulating not only SHP, but also these factors. Additionally, it remains unclear why SHP mRNA levels were altered by bile acids when ILF3 was knocked down. SHP functions as a transcriptional co-repressor for a wide array of nuclear receptors including LRH-1 and other transcriptional factors through direct binding with these targets, thereby interfering with their DNA binding and/or co-activator binding followed by the recruitment of corepressor complexes that contain HDACs [39] . Considering these mechanisms, reduced SHP expression by siILF3 may enhance the transactivation activity of these transcription factors and relax chromatin structure, thus resulting in increased SHP expression by bile acids. However, there is little evidence about the way in which ILF3 participates in the co-ordinated autoregulatory cascade in bile acid metabolism. Additional research is definitely needed to clarify this issue.
As described in both the present paper and our previous report [15] , ILF3 and Ku proteins function as transcriptional coregulators of LRH-1. LRH-1 is highly expressed in tissues such as the liver and intestine, where it governs the expression of genes involved in the homoeostasis of bile acids and cholesterol [1] . In contrast, ILF3 is ubiquitously expressed in mouse tissues [40] . Similarly, Ku proteins are also ubiquitous and abundant nuclear proteins. Although the specific role of ILF3 or Ku proteins in cholesterol homoeostasis has not yet been established, our current and previous findings [15] suggest that these proteins participate in cholesterol metabolism through regulation of gene expression mediated by LRH-1.
To date, several studies have shown that ILF3 and its isoform, NF90, form a complex with Ku proteins [41] [42] [43] . The chromatinbinding pattern of Ku proteins and NF90 (and/or ILF3) to the promoter correlates with the chromatin state and the gene expression level [43] . On the other hand, our results suggested that ILF3 and Ku proteins may form a discrete complex with LRH-1 ( Figure 1F ) and interact with LRH-1 by competing with each other for the same regions, the C and D regions of LRH-1 ( Figure 1C ) [15] . As for the effect on the transactivation activity of LRH-1, ILF3 and Ku proteins were shown to have the opposite effect ( Figure 2 ) [15] . Collectively, ILF3 (and/or NF90) and Ku proteins may form a complex and act simultaneously, in part, to regulate transcription, but further studies are needed to determine their role in transcriptional regulation.
Taken together, our results provide a model for how ILF3 and Ku proteins control the expression of genes involved in bile acid metabolism. ILF3 and Ku proteins may modulate SHP expression in a mutually exclusive manner. ILF3 activates its expression in concert with PRMT1 and PGC-1α. In contrast, Ku proteins could interfere with the interaction between ILF3 and LRH-1 and the co-activating function of PGC-1α [15] , resulting in decreased SHP expression. Previous reports showed that bile acids induce a negative-feedback regulation of their own synthesis mediated by nuclear receptors [3, 28] . However, under these circumstances, as well as in the absence of bile acids, ILF3 and Ku proteins may also act as cofactors of LRH-1 by altering gene expression. Thus, although it is quite likely that the interaction between ILF3 and LRH-1 is physiologically important for regulation of gene expression in cholesterol/bile acid homoeostasis, further studies are needed to elucidate the physiological function of ILF3 in tissues expressing LRH-1.
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